ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: EnteroMedics Inc. (ETRM) Report Updated: Sep 01, 2014 | Print This Page

Get more stock ratings by Louis Navellier

EnteroMedics Inc. (ETRM)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Health Care Equipment & Supplies
Competitors: ZLTQ, ERB, TFX, SNN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

EnteroMedics Inc.© quotemedia

Company Profile

EnteroMedics Inc., a clinical development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. The company is developing Maestro System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It is evaluating the Maestro System in human clinical trials in the United States, Australia, Mexico, Norway, and Switzerland. It has collaborations with Mayo Clinic and Australian Institute of Weight Control for research and development of its products. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

Recent News: EnteroMedics Inc.